This site is intended for healthcare professionals
Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
A randomised, double-blind, placebo-controlled trial of a novel beta-blocker, Carvedilol, in 1094 patients with symptomatic heart failure demonstrated a significant reduction in mortality and morbidity in the treatment group.
Patients had ejection fractions of <35%. Their current anti-failure treatment was not altered. Follow-up averaged 6.5 months.
The reduction in risk of death attributable to Carvedilol was 65% (95% confidence interval: 39-80%).
The reduction in risk of death or hospitalisation for cardiovascular causes attributable to Carvedilol was 38% (95% confidence interval: 18-53%).
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) also studied the use of a beta-blocker, bisoprolol, in patients with heart failure.